(Q35040837)

6 August 2017

1 reference

title

Cytochrome P450-based cancer gene therapy: current status (English)

1 reference

6 August 2017

0 references

1 reference

On Kan

1

1 reference

6 August 2017

Susan Kingsman

series ordinal

2

1 reference

6 August 2017

Stuart Naylor

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Biological Therapy

6 August 2017

1 reference

6 August 2017

2

1 reference

6 August 2017

8

1 reference

6 August 2017

857-868

1 reference

Locally advanced and metastatic bladder cancer

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Treatment options in hormone-refractory prostate cancer: current and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

New agents for the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Anti-tumour promoter activity in Malaysian ginger rhizobia used in traditional medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Cytochrome P450-based cancer gene therapy: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Characterization of physiologically regulated vectors for the treatment of ischemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Targeting gene expression to hypoxic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.8.857

21 January 2018

Identifiers

DOI

10.1517/14712598.2.8.857

1 reference

release_smbjkl22d5a5bflduepckoqsom

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/smbjkl22d5a5bflduepckoqsom

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference